Research peptide signals: studies and regulatory updates
A tracker of peer-reviewed studies, trial registrations and FDA and other regulator records on research peptides such as BPC-157, TB-500, MOTS-c, SS-31, Semax and DSIP.
Start here
How to read a research or regulatory signal
What a cell study, a phase 3 trial, a press release or an FDA list entry can and cannot tell you, with key regulatory vocabulary and a checklist for each signal.
FDA compounding committee, July 2026: seven research peptides on the agenda
FDA's Pharmacy Compounding Advisory Committee agenda for 23–24 July 2026 lists BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. Here is what the record says.
Elamipretide (SS-31): the 2025 accelerated approval on the record
SS-31 is a Szeto-Schiller tetrapeptide studied for its binding to cardiolipin. In September 2025 FDA granted accelerated approval to elamipretide for Barth syndrome. Here is what the record shows.
Prepared by: Research Desk. Sources are linked for verification.
What KlowSignal tracks
KlowSignal follows new primary records on research peptides and reports what they say, with a link to the source. Records fall into three groups:
- Peer-reviewed studies, including cell, animal and human research and systematic reviews. We note the model, such as "in rats", because early findings often do not carry over to people.
- Trial registrations and results, including trials that did not meet their primary endpoints.
- Regulator records from the US Food and Drug Administration (FDA) and other bodies, plus sport listings such as the World Anti-Doping Agency Prohibited List.
Compounds covered include BPC-157, TB-500, MOTS-c, SS-31 (elamipretide), Semax and DSIP (emideltide). For several of these, including BPC-157, TB-500 and MOTS-c, the published evidence is mainly preclinical. SS-31 is an exception: it has been studied in clinical trials and, as elamipretide, received an FDA accelerated approval for one rare disease.
How items are sourced and dated
Every item links to a primary record: a journal abstract, a registry entry or a regulator's own page. Updates that cannot be traced to such a record are left out. Each item shows the date of the record itself and the date its status was last checked, because regulatory status can change.
Latest signals
- FDA compounding committee, July 2026. The FDA meeting page lists BPC-157, KPV, TB-500 and MOTS-c for discussion on 23 July 2026, and emideltide (DSIP), Semax and Epitalon on 24 July 2026, as bulk drug substances being considered for inclusion on the 503A Bulks List. Separately, FDA's page of bulk drug substances that may present significant safety risks lists BPC-157 and "thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among substances whose category 2 nominations were withdrawn. Emideltide (DSIP) is also listed on that FDA page. Record dates: 23–24 July 2026 (meeting). Status last checked: 19 October 2026.
- Elamipretide accelerated approval. On 19 September 2025, FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome. According to FDA, the approval was based on an intermediate endpoint, and a confirmatory randomised, placebo-controlled trial is required. Research-grade SS-31 is not the approved product and is not covered by the approval. Record date: 19 September 2025. Status last checked: 19 October 2026.
Reading the signals
A new record is not new evidence of an effect: an advisory committee agenda is a scheduled discussion, not a decision, and a listing on a safety-risk page reflects FDA's review of a nomination rather than a finding about outcomes in people. Our guide on how to read a research signal explains study types and regulatory terms. For who runs the site and how corrections work, see About.
Supplier
Purita is a store that sells peptides for laboratory research use only, and its product pages label items for research use only and not for human or animal administration.
Affiliate disclosure: this is a paid link. KlowSignal earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.